Compare PJT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PJT | DYN |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.8B |
| IPO Year | 2015 | 2020 |
| Metric | PJT | DYN |
|---|---|---|
| Price | $150.84 | $17.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $178.50 | $37.00 |
| AVG Volume (30 Days) | 312.4K | ★ 2.8M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,713,671,000.00 | N/A |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $9.98 | N/A |
| P/E Ratio | $23.03 | ★ N/A |
| Revenue Growth | ★ 14.77 | N/A |
| 52 Week Low | $127.73 | $11.92 |
| 52 Week High | $195.62 | $27.31 |
| Indicator | PJT | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 27.44 | 22.61 |
| Support Level | $144.58 | $16.55 |
| Resistance Level | $163.37 | $19.54 |
| Average True Range (ATR) | 5.97 | 1.14 |
| MACD | -3.67 | -0.64 |
| Stochastic Oscillator | 3.28 | 0.87 |
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.